Looking Beyond Recurrence: Comorbidities in Cancer Survivors

被引:38
作者
Edgington, Amy [1 ]
Morgan, Mary Ann [1 ]
机构
[1] Univ Calif Los Angeles, LIVESTRONGTM Survivorship Ctr Excellence, Los Angeles, CA 90095 USA
关键词
D O I
10.1188/11.CJON.E3-E12
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer recurrence is a very real concern for cancer survivors. Surveillance for recurrence and vigilance for development of new cancers are top priorities during follow-up visits after active treatment ends. However, the cancer survivor also is at risk for the development of comorbid conditions. These conditions, including obesity, diabetes, dyslipidemia, menopause, decreased bone mass, hypertension, and hypothyroidism, are discussed with their relevance for general health and their relationships to disease-specific cancers. All of these conditions should be routinely addressed as part of the patient's survivorship care when appropriate. The oncology nurse is in a prime position to educate survivors about the risks for these conditions, both through evidence-based practice guidelines specific to each condition and also through the use of a treatment summary and care plan. This article discusses these selected comorbidities and offers strategies for nurses to address them with survivors during follow-up visits. Clinical practice guidelines for comorbidities are included, along with oncology implications and relevance for survivors. Recommendations for modifiable risk factors and healthy living also are included, along with Web sites for survivorship care plans.
引用
收藏
页码:31 / 31
页数:1
相关论文
共 71 条
  • [31] Gibaldi M., Bioequivalence of thyroid preparations: The final word?, American Association of Pharmaceutical Scientists, 7, (2005)
  • [32] Gnant M.F., Mlineritsch B., Luschin-Ebengreuth G., Grampp S., Kaessmann H., Schmid M., Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group, Journal of Clinical Oncology, 25, pp. 820-828, (2007)
  • [33] Goodwin P., Vitamin D in Cancer Patients: Above All, Do No Harm, (2009)
  • [34] Grundy S., Obesity, metabolic syndrome, and cardiovascular disease, Journal of Clinical Endocrinology and Metabolism, 89, pp. 2595-2600, (2004)
  • [35] Hewitt M., Greenfield S., Stovall E., From Cancer Patient to Cancer Survivor: Lost in Transition, (2006)
  • [36] Hewitt M., Rowland J., Yancik R., Cancer survivors in the United States: Age, health, and disability, Journal of Gerontology, 58, pp. 82-91, (2003)
  • [37] Hu F.B., Manson J.E., Liu S., Hunter D., Colditz G.A., Michels K.B., Giovannucci E., Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women, Journal of the National Cancer Institute, 91, pp. 542-547, (1999)
  • [38] Izzedine H., Ederhy S., Goldwasser F., Soria J.C., Milano G., Cohen A., Spano J.P., Management of hypertension in angiogenesis inhibitor-treated patients, Annals of Oncology, 20, pp. 807-815, (2009)
  • [39] Jain M., Townsend R., Chemotherapy agents and hypertension: A focus on angiogenesis blockage, Current Hypertension Reports, 9, pp. 320-328, (2007)
  • [40] Katzung B.G., Basic and Clinical Pharmacology, (2004)